Published • loading... • Updated
Boehringer pays up to $250M to expand Variant Bio's pact into heart disease - European Biotechnology Magazine
Summary by European-biotechnology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Boehringer pays up to $250M to expand Variant Bio's pact into heart disease - European Biotechnology Magazine
Boehringer Ingelheim has expanded its partnership with Variant Bio into cardiovascular disease, adding potential payments exceeding $250 million (€219 million). The agreement builds on a kidney disease collaboration signed in January.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
